» Articles » PMID: 20153980

Shaping of INKT Cell Repertoire After Unrelated Cord Blood Transplantation

Overview
Journal Clin Immunol
Date 2010 Feb 16
PMID 20153980
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Invariant natural killer T (iNKT) cells have a pivotal role in immune regulation, tumor surveillance, and the induction of allograft tolerance. In this report, we analyze the recovery of iNKT cells after unrelated cord blood transplantation (UCBT) of adult patients with high-risk acute myeloid leukemia. We found that iNKT cells were reconstituted within 1 month after UCBT, at the same time as NK cells and before conventional T cells. These iNKT cells displayed a unique primed/central memory CD4(+)CD45RO(+)CCR7(+)CD62L(+) phenotype soon after the transplant. Interestingly, the functional competence of these cells was poor, except for their high GM-CSF production capacity. However, this post-graft functionally immature state was transient and all of the patients tested had fully functional iNKT cells 3 to 6 months post-UCBT and high cytolytic capacity for destroying primary CD1d(+) myeloid blast cells. Our results raise the possibility that iNKT cells might play a key role in graft-versus-leukemia activity after UCBT.

Citing Articles

Graft-versus-Host Disease Modulation by Innate T Cells.

Fang Y, Zhu Y, Kramer A, Chen Y, Li Y, Yang L Int J Mol Sci. 2023; 24(4).

PMID: 36835495 PMC: 9962599. DOI: 10.3390/ijms24044084.


Ageing-resembling phenotype of long-term allogeneic hematopoietic cells recipients compared to their donors.

Cezary Czarnogorski M, Sakowska J, Maziewski M, Zielinski M, Piekarska A, Obuchowski I Immun Ageing. 2022; 19(1):51.

PMID: 36324179 PMC: 9628063. DOI: 10.1186/s12979-022-00308-6.


iNKT cells coordinate immune pathways to enable engraftment in nonconditioned hosts.

Hess N, Bharadwaj N, Bobeck E, McDougal C, Ma S, Sauer J Life Sci Alliance. 2021; 4(7).

PMID: 34112724 PMC: 8200291. DOI: 10.26508/lsa.202000999.


Reconstitution of T Cell Subsets Following Allogeneic Hematopoietic Cell Transplantation.

Dekker L, de Koning C, Lindemans C, Nierkens S Cancers (Basel). 2020; 12(7).

PMID: 32698396 PMC: 7409323. DOI: 10.3390/cancers12071974.


Development of Hematopoietic Stem Cell-Engineered Invariant Natural Killer T Cell Therapy for Cancer.

Zhu Y, Smith D, Zhou Y, Li Y, Yu J, Lee D Cell Stem Cell. 2019; 25(4):542-557.e9.

PMID: 31495780 PMC: 7018522. DOI: 10.1016/j.stem.2019.08.004.